Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications

Area of Science:

• Health Services Research
• Health Policy
• Evidence-Based Medicine

Background:

• The 21st Century Cures Act mandates public accessibility of evidence summaries for Medicare local coverage determinations (LCDs).
• LCDs are crucial for Medicare's coverage decisions on new healthcare technologies.
• Transparency in evidence supporting these decisions is vital for understanding coverage rationale.

Purpose of the Study:

• To assess the availability and quality of evidence supporting Medicare LCDs for drugs, biologics, and devices.
• To compare evidence strength and generalizability between favorable and unfavorable coverage decisions.
• To evaluate the impact of the 21st Century Cures Act on evidence transparency.

Main Methods:

• Analysis of Medicare Coverage Database reports and the medical literature for LCDs from 2015-2022.
• Examination of evidence summaries' public availability and the characteristics of cited studies.
• Comparison of evidence sources, patient demographics (age, race, ethnicity), and study design strength for covered vs. non-covered indications.

Main Results:

• Public availability of evidence summaries increased from 26% (2015-18) to 100% (2019-22).
• Favorable indications cited more evidence sources (median 4 vs. 2) and studies with older patients (78% vs. 47%) compared to non-covered ones.
• Study design strength did not correlate with coverage decisions; less than one-third of studies reported race/ethnicity.

Conclusions:

• While the 21st Century Cures Act enhanced transparency of evidence for Medicare coverage decisions, significant gaps remain.
• Clinical evidence supporting favorable coverage often lacks diversity and may not fully represent the Medicare beneficiary population.
• Further efforts are needed to ensure evidence used in LCDs is generalizable and reflective of diverse patient groups.